134 related articles for article (PubMed ID: 10908682)
21. Endogenous BDNF protein is increased in adult rat hippocampus after a kainic acid induced excitotoxic insult but exogenous BDNF is not neuroprotective.
Rudge JS; Mather PE; Pasnikowski EM; Cai N; Corcoran T; Acheson A; Anderson K; Lindsay RM; Wiegand SJ
Exp Neurol; 1998 Feb; 149(2):398-410. PubMed ID: 9500963
[TBL] [Abstract][Full Text] [Related]
22. Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector.
Kaplitt MG; Kwong AD; Kleopoulos SP; Mobbs CV; Rabkin SD; Pfaff DW
Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8979-83. PubMed ID: 8090756
[TBL] [Abstract][Full Text] [Related]
23. Chemical adrenalectomy reduces hippocampal damage induced by kainic acid.
Stein BA; Sapolsky RM
Brain Res; 1988 Nov; 473(1):175-80. PubMed ID: 3208122
[TBL] [Abstract][Full Text] [Related]
24. Over-expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults.
Wang H; Cheng E; Brooke S; Chang P; Sapolsky R
J Neurochem; 2003 Dec; 87(6):1527-34. PubMed ID: 14713308
[TBL] [Abstract][Full Text] [Related]
25. Neighbor effects of neurons bearing protective transgenes.
Lee AL; Campbell LB; Sapolsky RM
Brain Res; 2010 Jun; 1339():70-5. PubMed ID: 20417625
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotection of adenoviral-vector-mediated GDNF expression against kainic-acid-induced excitotoxicity in the rat hippocampus.
Yoo YM; Lee CJ; Lee U; Kim YJ
Exp Neurol; 2006 Aug; 200(2):407-17. PubMed ID: 16690057
[TBL] [Abstract][Full Text] [Related]
27. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector.
Ichikawa T; Chiocca EA
Cancer Res; 2001 Jul; 61(14):5336-9. PubMed ID: 11454670
[TBL] [Abstract][Full Text] [Related]
28. 2-Deoxy-D-glucose protects hippocampal neurons against excitotoxic and oxidative injury: evidence for the involvement of stress proteins.
Lee J; Bruce-Keller AJ; Kruman Y; Chan SL; Mattson MP
J Neurosci Res; 1999 Jul; 57(1):48-61. PubMed ID: 10397635
[TBL] [Abstract][Full Text] [Related]
29. Herpes simplex virus type 1 vector mediated gene transfer to muscle.
Huard J; Goins WF; Glorioso JC
Gene Ther; 1995 Aug; 2(6):385-92. PubMed ID: 7584113
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective effects of an adenoviral vector expressing the glucose transporter: a detailed description of the mediating cellular events.
Gupta A; Ho DY; Brooke S; Franklin L; Roy M; McLaughlin J; Fink SL; Sapolsky RM
Brain Res; 2001 Jul; 908(1):49-57. PubMed ID: 11457430
[TBL] [Abstract][Full Text] [Related]
31. Minireview: the herpes simplex virus amplicon--a versatile defective virus vector.
Frenkel N; Singer O; Kwong AD
Gene Ther; 1994; 1 Suppl 1():S40-6. PubMed ID: 8542394
[TBL] [Abstract][Full Text] [Related]
32. Gene therapies that enhance hippocampal neuron survival after an excitotoxic insult are not equivalent in their ability to maintain synaptic transmission.
Dumas TC; McLaughlin JR; Ho DY; Lawrence MS; Sapolsky RM
Exp Neurol; 2000 Nov; 166(1):180-9. PubMed ID: 11031094
[TBL] [Abstract][Full Text] [Related]
33. Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression.
Lu B; Federoff HJ
Hum Gene Ther; 1995 Apr; 6(4):419-28. PubMed ID: 7612699
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of the glucose transporter gene with a herpes simplex viral vector protects striatal neurons against stroke.
Lawrence MS; Sun GH; Kunis DM; Saydam TC; Dash R; Ho DY; Sapolsky RM; Steinberg GK
J Cereb Blood Flow Metab; 1996 Mar; 16(2):181-5. PubMed ID: 8594048
[TBL] [Abstract][Full Text] [Related]
35. Delivery of herpes simplex virus amplicon-based vectors to the dentate gyrus does not alter hippocampal synaptic transmission in vivo.
Dumas T; McLaughlin J; Ho D; Meier T; Sapolsky R
Gene Ther; 1999 Oct; 6(10):1679-84. PubMed ID: 10516716
[TBL] [Abstract][Full Text] [Related]
36. Gene therapy effectiveness differs for neuronal survival and behavioral performance.
Phillips RG; Monje ML; Giuli LC; Meier TJ; Yenari MA; Kunis D; Sapolsky RM
Gene Ther; 2001 Apr; 8(8):579-85. PubMed ID: 11320403
[TBL] [Abstract][Full Text] [Related]
37. Gene therapy for treatment of cerebral ischemia using defective herpes simplex viral vectors.
Yenari MA; Dumas TC; Sapolsky RM; Steinberg GK
Neurol Res; 2001 Jul; 23(5):543-52. PubMed ID: 11474812
[TBL] [Abstract][Full Text] [Related]
38. Genetic analysis of neuronal physiology with defective herpes simplex virus vectors.
Neve RL; Geller AI
Adv Neurol; 1999; 79():1027-32. PubMed ID: 10514884
[No Abstract] [Full Text] [Related]
39. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors.
Costantini LC; Jacoby DR; Wang S; Fraefel C; Breakefield XO; Isacson O
Hum Gene Ther; 1999 Oct; 10(15):2481-94. PubMed ID: 10543613
[TBL] [Abstract][Full Text] [Related]
40. Blocking glucocorticoid and enhancing estrogenic genomic signaling protects against cerebral ischemia.
Cheng MY; Sun G; Jin M; Zhao H; Steinberg GK; Sapolsky RM
J Cereb Blood Flow Metab; 2009 Jan; 29(1):130-6. PubMed ID: 18797472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
